<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="of combinations of HBPG and either ACV, phosphonoformate (PFA), or" exact="cidofovir" post="(CDF) against HSV encephalitis. BALB/c mice were given ocular"/>
 <result pre="therapy of newborns with localized or disseminated HSV disease, although" exact="vidarabine" post="and phosphonoformate (PFA) have also been used. Although these"/>
 <result pre="Ocular infection Mice were anesthetized by intraperitoneal (IP) injection of" exact="ketamine" post="(200 mg/kg) and xylazine (20 mg/kg), their corneas lightly"/>
 <result pre="virus (to yield 150â€“250 PFU/well). Test compounds were dissolved in" exact="dimethyl sulfoxide" post="(DMSO) at 10 mg/mL, and diluted in overlay medium"/>
 <result pre="example, a ribonucleotide reductase inhibitor potentiated activity of ACV,15 and" exact="docosanol" post="was synergistic with various nucleoside analogs.16 These findings are"/>
 <result pre="Sci U S A198986105110552536930 16MarcellettiJFSynergistic inhibition of herpesvirus replication by" exact="docosanol" post="and antiviral nucleoside analogsAntivir Res20025615316612367721 17ChoCTFengKKCombined effects of acycloguanosine"/>
 <result pre="ED50, mg/kgb HSV-1 HSV-2 ACV 82 90 PFA 200 300" exact="cidofovir" post="3.2 2.4 HBPG 150 103 Notes: aOcular infection with"/>
</results>
